arrow
M

M. Duruisseaux

hospices civils de lyon cancer institute
H指数:32
被引数:3,807

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the KRYSTAL-12 study results: adagrasib for non−small cell lung cancer with KRASG12C mutations

KRYSAL-12研究的通俗结果摘要:针对KRASG12C突变的非小细胞肺癌的adagrasib治疗

2026-09-160
OAAI
Female pulmonologists experienced poorer health and reduced quality of life related to their professional activities

女性肺科医生因专业活动经历更差的健康状况和降低的生活质量

2026-04-130
PRE
Accelerating recruitment in clinical trials: A strategic challenge

加速临床试验中的招募:一项战略挑战

2026-01-010
PRE
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib 与多西他赛在 KRASG12C 突变非小细胞肺癌中的比较(KRYSTAL-12):一项随机、开放标签、III 期临床试验

2025-08-070
PRE
Clinical outcomes of compound EGFR mutations in non-small cell lung cancer: A national, retrospective, multicenter study.

非小细胞肺癌中复合EGFR突变的治疗效果:一项全国性、回顾性、多中心研究。

2025-06-250
PREAI
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

LIBELULE研究:一项随机III期研究,旨在评估早期液体活检在可疑转移性肺癌患者中的临床相关性。

2024-12-012
OAAI
French pulmonologists suffered from impaired health and quality of life due to their work
2024-10-300
PRE
Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study

循环hPG80(WNT通路激活)作为免疫治疗(ICI)疗效的潜在新预后/预测因素:ONCOPRO前瞻性研究

2024-09-010
PRE
Non-adenocarcinoma histology in patients with RET plus lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry

RET融合阳性肺癌患者中的非腺癌组织学特征:来自RET-MAP登记研究的RET抑制剂疗效与生存分析

2024-09-010
PRE
Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study

非小细胞肺癌(NSCLC)中循环核小体的预后价值:接受或不接受免疫治疗治疗期间的结果——来自NUCLEO-lung研究

2024-09-010
PRE
Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

度伐利尤单抗(Durvalumab)治疗初治、IV期非小细胞肺癌(NSCLC)患者(pts),其中ECOG体力状态(PS)评分为2-3且PD-L1肿瘤表达水平高:IFCT-1802 SAVIMMUNE II期试验结果

2024-09-010
PRE